1. Articles from businesswire.com

  2. 1-24 of 85 1 2 3 4 »
    1. Perimeter Medical Imaging AI Reports Third Quarter 2021 Financial Results and Provides Corporate Update

      Perimeter Medical Imaging AI Reports Third Quarter 2021 Financial Results and Provides Corporate Update

      The net loss for the three months ended September 30, 2021 was $3,880,172 compared to the net income of $800,030 for the three months ended September 30, 2020. For the nine months ended September 30, 2021, cash used in operating activities was $10,032,107. As of September 30, 2021, cash and cash equivalents were $7,775,195 and investments were $794,000

      Read Full Article
    2. Perimeter Medical Imaging AI Announces Important Milestone in Atlas Ai Project With FDA Investigational Device Exemption (IDE) Approval to Launch Clinical Trial Using Perimeter B-Series OCT With ImgAssist AI in Breast Conservation Surgery

      Perimeter Medical Imaging AI Announces Important Milestone in Atlas Ai Project With FDA Investigational Device Exemption (IDE) Approval to Launch Clinical Trial Using Perimeter B-Series OCT With ImgAssist AI in Breast Conservation Surgery

      erimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced approval of its Investigational Device Exemption (“IDE”) application by the U.S. Food and Drug Administration (“FDA”) to conduct a multi-center, randomized, double-arm study to evaluate the FDA breakthrough-device-designated Perimeter B-Series OCT imaging system that uses ImgAssist AI technology to identify regions of interest as compared with the current standard of care for patients undergoing breast conservation surgery. It is anticipated that ...

      Read Full Article
    3. Neurovascular Interventional Devices for Hemorrhagic Stroke - Global Market Analysis and Outlook 2020-2025 - ResearchAndMarkets.com

      Neurovascular Interventional Devices for Hemorrhagic Stroke - Global Market Analysis and Outlook 2020-2025 - ResearchAndMarkets.com

      DUBLIN--(BUSINESS WIRE)--Oct 8, 2021-- The "Global Neurovascular Interventional Devices for Hemorrhagic Stroke Market" report has been added to ResearchAndMarkets.com 's offering. This report covers the impact of COVID-19 on the neurovascular interventional devices for hemorrhagic stroke market, including a recent forecast from 2020 to 2025. COVID-19 has impacted leading competitors, such as Abbott, Boston Scientific, Cardinal Health, Penumbra, Stryker, Terumo, and others.

      Read Full Article
    4. Next Generation ASC Laser Controller Solution Is Now Available

      Next Generation ASC Laser Controller Solution Is Now Available

      ARGES, a product brand of Novanta Corporation (“Novanta”), announces the addition of its new laser controller, ASC Generation 4 to its ASC series portfolio. This new controller features powerful performance thanks to updated electronics, changeable multi-functional interface boards for added flexibility, and open platform with embedded Linux OS. This controller solution is compatible with all ARGES scan heads, lasers, and sub-systems. Packed with enhanced features and performance, this next generation controller works seamlessly with our proprietary software, InScript for a complete laser control solution. Our cross-collaborative team has worked tirelessly to develop a controller platform that enables a new level ...

      Read Full Article
    5. PHC Corporation of North America and SCREEN Partner to Promote 3D Live Cell Imaging in North America

      PHC Corporation of North America and SCREEN Partner to Promote 3D Live Cell Imaging in North America

      PHC Corporation of North America (PHCNA) and SCREEN Holdings Co., Ltd. have today announced the formation of a partnership to market and sell the SCREEN Cell3iMager series of live-cell imaging systems in North America. These innovative ex vivo imaging instruments enable organoid and spheroid imaging with excellent accuracy using high-throughput, high-speed, and non-invasive technology for cellular research, drug discovery, cosmetic and biopharmaceutical applications. SCREEN’s instrument portfolio includes high speed bright-field spheroid imagers, multi-fluorescence imaging in 2D and 3D, as well as live-cell imaging by optical coherence tomography (OCT). The instruments will be available alongside PHCbi’s current portfolio of ...

      Read Full Article
    6. Perimeter Medical Imaging AI Reports Second Quarter 2021 Financial Results and Provides ...

      Perimeter Medical Imaging AI Reports Second Quarter 2021 Financial Results and Provides ...

      Summary of Second Quarter 2021 Financial Results: All of the amounts are expressed in Canadian dollars unless otherwise indicated and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including International Accounting Standard (“IAS”) 34, Interim Financial Reporting. Operating expenses for the three months ended June 30, 2021 were $3,056,431 compared to $1,997,959 during the same period in 2020. The net loss for the three months ended June 30, 2021 of $3,238,722 compared to $4,659,480 ...

      Read Full Article
    7. Perimeter Medical Imaging AI Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Perimeter Medical Imaging AI Reports First Quarter 2021 Financial Results and Provides Corporate Update

      All of the amounts are expressed in Canadian dollars unless otherwise indicated and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including International Accounting Standard (“IAS”) 34, Interim Financial Reporting. Operating expenses for the three months ended March 31, 2021 were $3,820,246 compared to $1,730,564 during the same period in 2020. The net loss for the three months ended March 31, 2021 was $4,015,732 compared to $1,792,611 for the same period in 2020. For ...

      Read Full Article
    8. New Study Demonstrates Exceptional Performance With Cardiovascular Systems' Diamondback 360

      New Study Demonstrates Exceptional Performance With Cardiovascular Systems' Diamondback 360

      Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world optical coherence tomography (OCT) imaging study of coronary OAS patients were released at EuroPCR 2021. The study conducted by Surendra Avula, MD, et al, at the University of Illinois, Chicago, was designed to assess the dual mechanism of action of orbital atherectomy. Twenty consecutive patients with severely calcified lesions identified by coronary angiography were enrolled and treated by a single operator. All patients received a prespecified treatment algorithm ...

      Read Full Article
    9. Perimeter Medical Imaging AI Reports 2020 Financial Results and Provides Corporate Update

      Perimeter Medical Imaging AI Reports 2020 Financial Results and Provides Corporate Update

      Summary 2020 Financial Results All of the amounts are expressed in Canadian dollars unless otherwise indicated and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including International Accounting Standard (“IAS”) 34, Interim Financial Reporting. Operating expenses for the year ended 2020 were $10,159,444 compared to $8,708,853 during the previous year. For the year ended December 31, 2020, the net loss was $7,885,966 compared to $10,342,686 in the prior year. For the year ended December ...

      Read Full Article
    10. Perimeter Medical Imaging AI Announces Important Milestone in ATLAS AI Project with Standalone AI Algorithm Achieving Key Performance Metrics

      Perimeter Medical Imaging AI Announces Important Milestone in ATLAS AI Project with Standalone AI Algorithm Achieving Key Performance Metrics

      Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced significant progress within its ATLAS AI Project, an initiative aimed at advancing Perimeter’s next-gen artificial intelligence (AI) and machine learning tools through clinical development. Perimeter’s proprietary “ImgAssist” AI technology has now been trained with more than 400 volumes of images of excised breast tissue collected during the first stage of its ATLAS AI project.

      Read Full Article
    11. Physician-Led Webinar Sponsored by Perimeter Medical Imaging AI Highlights Advancements in Intraoperative Specimen Imaging

      Physician-Led Webinar Sponsored by Perimeter Medical Imaging AI Highlights Advancements in Intraoperative Specimen Imaging

      Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that a physician-led webinar – organized by Perimeter as an industry event through the American Society of Breast Surgeons (ASBrS) – is now available for replay on Perimeter’s website . Perimeter recently announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Optical Coherence Tomography (OCT) Imaging System (v2.1), which is designed to examine tissue microstructures ...

      Read Full Article
    12. Acucela to Participate in Biotech Showcase™ 2020

      Acucela to Participate in Biotech Showcase™ 2020

      Retinal Health Remote Monitoring Device (eyeMO®). A home-based, patient self-monitoring miniature optical coherence tomography (OCT) device, eyeMO® is designed to detect nascent disease progression and support patient re-treatment prior to irreversible vision loss due to disease progression from neovascular retinal diseases.

      Read Full Article
      Mentions: Acucela
    13. Specsavers Uses Topcon OCT In Its Stores

      Specsavers Uses Topcon OCT In Its Stores

      Topcon Healthcare Solutions, Inc., a wholly-owned subsidiary of Topcon America Corporation (“Topcon”) based in Oakland, NJ, has announced that eye health provider Specsavers had recently completed equipping its stores with Topcon's Optical Coherence Tomography (OCT) instruments. On September 21, 2018, Specsavers had reported that Specsavers Blacktown (NSW) had become the 200th store in Australia and New Zealand (ANZ) to have OCT technology. An OCT is often used for the early detection of sight-threatening diseases such as glaucoma, diabetic retinopathy and age-related macular degeneration (AMD). Topcon’s OCT technology is now a part of every eye exam. With this consistent ...

      Read Full Article
    14. Optovue Announces Retirement of Prominent Industry Veteran John Hawley

      Optovue Announces Retirement of Prominent Industry Veteran John Hawley

      - Optovue the global leader in the development of optical coherence tomography ( OCT ) and OCT angiography ( OCTA ), today announced the retirement of renowned industry veteran John Hawley, the company’s senior vice president of global sales. Hawley will retire on July 1, 2018 and remain with Optovue in an advisory role. Prominent industry veteran John Hawley retires from Optovue. Tweet this “For the past 10 years, I have worked side-by-side with John as we built Optovue from a fledgling start-up to the global company we are today,” said Jay Wei, founder and chief executive officer of Optovue. “As a result of ...

      Read Full Article
      Mentions: Visionix
    15. Teledyne Imaging Receives Gold and Silver Awards from Vision Systems Design

      Teledyne Imaging Receives Gold and Silver Awards from Vision Systems Design

      Teledyne Technologies Incorporated (NYSE:TDY) announced today that Teledyne DALSA and Teledyne e2v were awarded Gold and Silver 2018 Innovator Awards from Vision Systems Design . This annual program celebrates innovative technologies, products and systems found in the machine vision and image processing market. Winners were selected by a panel of judges comprised of systems integrators, consultants and academics with years of experience in specifying, designing and configuring image processing and machine vision systems. Teledyne DALSA won Gold-level honors for its Linea CMOS multi-channel line scan machine vision camera. Used in advanced machine vision and automated inspection systems, Teledyne DALSA’s ...

      Read Full Article
      Mentions: Dalsa e2v
    16. Optovue Highlights AngioVue Essential OCTA at AAO

      Optovue Highlights AngioVue Essential OCTA at AAO

      Optovue , the global leader in the development of optical coherence tomography ( OCT ) and OCT angiography ( OCTA ), will highlight its AngioVue® Essential OCTA capability for general ophthalmology, along with its suite of advanced eye care technology at the upcoming American Academy of Ophthalmology Annual Meeting (AAO), Nov. 11-14 in New Orleans. The company will also host an OCT and OCT Angiography Interpretation Lab offering small group sessions, led by industry experts, for learning the fundamentals of OCTA in retinal disease and glaucoma, as well as epithelial thickness mapping in refractive practice. And, in celebration of three years of OCT Angiography, Optovue ...

      Read Full Article
      Mentions: Visionix
    17. Heidelberg Engineering Receives FDA Clearance to Market SPECTRALIS® OCT Glaucoma Module Premium Edition

      Heidelberg Engineering Receives FDA Clearance to Market SPECTRALIS® OCT Glaucoma Module Premium Edition

      The Glaucoma Module Premium Edition for SPECTRALIS provides a comprehensive analysis of the optic nerve head, retinal nerve fiber layer, and ganglion cell layer by precisely matching unique scan patterns to the fine anatomic structures relevant in glaucoma diagnostics. By means of a new proprietary technology called the Anatomic Positioning System, the module creates an anatomic map unique to each patient’s eye using two fixed, structural landmarks: the center of the fovea and the center of Bruch’s membrane opening. All subsequent scan protocols are automatically oriented according to each eye’s unique anatomic map, enabling a precise examination ...

      Read Full Article
    18. NinePoint Medical Announces Completion of Clinical Registry and Publication of Results at DDW 2016

      NinePoint Medical Announces Completion of Clinical Registry and Publication of Results at DDW 2016

      NinePoint Medical, Inc., a transformative medical device company pioneering the use of an advanced imaging platform for gastrointestinal applications, announced today that it has completed the primary phase of its Registry for High Resolution Optical Imaging of the Esophagus Using the NvisionVLE ® Imaging System. Results from the registry’s interim analysis will be presented in 11 scientific abstracts accepted to Digestive Disease Week ® (DDW) 2016, to be held May 21-24 in San Diego, California.

      Read Full Article
    19. ZEISS Presents Innovations That Support Ophthalmologists in Their Work

      ZEISS Presents Innovations That Support Ophthalmologists in Their Work

      At the 2015 Annual Meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, ZEISS announces innovations for clinical excellence and practice performance in ophthalmology. In the field of retina and glaucoma, doctors can expand their treatment option based on the innovative ZEISS AngioPlex OCT Angiography that provides three-dimensional representations of the retina and the choroid, eliminating the risk of adverse reactions caused by injections into the eye: Blood vessels can now be displayed using optical coherence tomography (OCT). Furthermore, two new fundus cameras offer more detailed views in the diagnosis and follow-up of eye diseases. Cataract surgeons can ...

      Read Full Article
    20. ZEISS Sets the Pace in OCT Innovation with First FDA 510(k) Clearance of OCT Angiography Technology

      ZEISS Sets the Pace in OCT Innovation with First FDA 510(k) Clearance of OCT Angiography Technology

      D ZEISS Medical Technology announces that its AngioPlex OCT Angiography is the first such technology to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA). “OCT angiography ushers in a new era in the evaluation of the retina in diabetic retinopathy and macular degeneration” With a single additional OCT scan that takes just seconds on the CIRRUS HD-OCT system from ZEISS, ophthalmologists can now utilize optical coherence tomography (OCT) images to assess the blood vessels (vasculature) of the retina at a depth and clarity never available before. AngioPlex OCT Angiography delivers high-resolution, depth-resolved visualization of the ...

      Read Full Article
    21. New Journal Article Highlights Mechanical Effects of Orbital Atherectomy and Rotational Atherectomy in Treating Heavily Calcified Coronary Lesions

      New Journal Article Highlights Mechanical Effects of Orbital Atherectomy and Rotational Atherectomy in Treating Heavily Calcified Coronary Lesions

      Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that a new article e-published in May 2015 in The Journal of Catheterization and Cardiovascular Intervention highlights the mechanical effect of orbital atherectomy (OA) and rotational atherectomy (RA) in treating heavily calcified coronary lesions. ” The article, titled “Optical Coherence Tomography Assessment of the Mechanistic Effects of Rotational and Orbital Atherectomy in Severely Calcified Coronary Lesions,” details results from a study led by Dr. Annapoorna Kini, Professor of Cardiology at the Mount Sinai Hospital and Icahn School of Medicine, and Director of The Cardiac Catheterization Lab at Mount Sinai Hospital. Said study co-investigator ...

      Read Full Article
    22. “How Does Breast Cancer Develop?” Pilot Grants Awarded to Multidisciplinary Teams Using the Intraductal Approach to Advance Breast Cancer Prevention

      “How Does Breast Cancer Develop?” Pilot Grants Awarded to Multidisciplinary Teams Using the Intraductal Approach to Advance Breast Cancer Prevention

      Dr. Sheldon Feldman and Dr. Fatih Balci study intraductal approaches to breast cancer. They are currently investigating the effectiveness of optical coherence tomography (OCT), which is used in cardiology to look at blood vessels from the inside using light instead of sound (as an ultrasound does) to create three-dimensional images. OCT may be able to identify early changes in the breast duct before ductal carcinoma in situ (DCIS) or cancer forms. This consortium received $17,000 to study whether it is feasible to use OCT to distinguish different types of breast cells and tissues and whether OCT can show features ...

      Read Full Article
    23. Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

      Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

      Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Barry Gertz, MD, PhD, and Jay S. Duker, MD, to the company’s Board of Directors. Each of these new Board members brings more than 25 years of experience that is relevant to Eleven’s progress in advancing its pipeline of innovative therapies for ocular diseases. “We are excited to add these two highly accomplished industry and academic leaders to round out our Board. Their strategic support and guidance will be key as we continue to advance our ...

      Read Full Article
    24. Engaged Capital Sends Letter to the Board of Volcano Corporation

      Engaged Capital Sends Letter to the Board of Volcano Corporation

      Engaged Capital, an investment firm specializing in small and mid-cap North American equities and beneficial owner of approximately 2,638,403 shares of the common stock of Volcano Corporation (“VOLC” or the “Company”) (Nasdaq:VOLC), today sent an open letter http://engagedcapital.com/press/VOLCBODLetter.pdf to the Company’s Board of Directors (the “Board”), filed with the U.S. Securities and Exchange Commission. “It is time for new leadership. We urge the Board to immediately commence a parallel process to evaluate strategic alternatives and conduct a search for CEO candidates with a history of driving profitability and extracting value ...

      Read Full Article
    1-24 of 85 1 2 3 4 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks